Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...

A new study shows how pathogens control changes in their cell surface to evade the immune system. A new study by LMU and Helmholtz Munich shows how pathogens control changes in their cell surface to ...

An international research team with strong participation from DTU has developed a new biotechnological platform that makes it possible to test and understand advanced cancer treatments much faster and ...

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a ...

A structurally tuned HPV cancer SNA vaccine boosts CD8⁺ T‑cell responses and slows tumor growth in mice and patient‑derived spheroids, a study shows.

A new vaccine design uses folded DNA to steer the immune system toward producing the rare immune cells needed to make ...

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...